Multicontext Approach to Help Daily Thinking in Parkinson’s

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

People with early Parkinson’s commonly experience mild cognitive decline that can affect daily activities and quality of life. This trial uses the Multicontext Approach, a metacognitive strategy training, to help participants develop everyday strategies to cope with cognitive challenges. Participants undergo a combination of metacognitive strategy training, cognitive processing training, and booster sessions aimed at improving awareness and use of strategies in real-life tasks. The study targets individuals aged 50 and older with idiopathic Parkinson’s, Hoehn and Yahr stages I–III, who report subjective cognitive concerns and can identify daily cognitive tasks they want to address. Eligibility requires stable medications for a period before the treatment and exclusion of dementia or major psychiatric disorders. The sponsor is Washington University School of Medicine, with the trial conducted at that center.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Males and females over age 50 who meet criteria for typical idiopathic PD.
2. Hoehn \& Yahr stage I-III.
3. Have subjective cognitive decline (SCD) as defined by a positive answer to either question:

   * Do you feel like your thinking skills or memory are becoming worse or are worse than others your age?
   * Do you have problems or concerns with your thinking skills or memory?, and can list ≥1 daily cognitive challenge they want to address.
4. Medications should be stable for 4 weeks prior with no changes planned during the treatment portion of the study (Pre to Post); unplanned changes and changes over the follow-up period will be tracked and accounted for as appropriate.

Exclusion criteria:

1. Dementia according to MDS criteria or MoCA score \<21.
2. Other neurological disorders (e.g., stroke, seizures).
3. Current or history of major psychiatric disorder or psychotic symptoms (e.g., schizophrenia, bipolar disorder, delusions, hallucinations), drug abuse. Psychiatric conditions/symptoms that are common in PD (e.g., anxiety, depression) are permitted if deemed insufficient to interfere with participation.
4. Other circumstance that would interfere with participation (e.g., non-English speaking, blindness, lives \>50mi away).

Where it's running

• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Erin R Foster, PhD, OTDR/L — Washington University School of Medicine
• Study coordinator: Tasha D Doty, MA
• Email: tdoty@wustl.edu
• Phone: 785-865-8943

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• UX-DA003 injections for Parkinson's disease

  This early-phase trial tests whether injecting UX-DA003 is safe and may help motor symptoms in people with Parkinson's whose response to standard treatments has declined.

  Recruiting Early Phase 1 The First Affiliated Hospital of Anhui Medical University · Hefei, Anhui · NCT07911670

• Strength and dual-task training to help people with Parkinson’s improve strength and function

  This trial tests three levels of physiotherapy, including progressive resistance training with and without cognitive dual-task and instability components, to see if they improve muscle strength, body composition, and physical function in adults with Parkinson’s or related syndromes.

  Recruiting University of Valencia · Valencia, Valencia · NCT07907302

• Spinal Mobility, Rigidity, and Kinesiophobia in Parkinson's Disease with and without TMD

  This study tests whether people with Parkinson's disease who have Temporomandibular Disorders differ in spinal mobility, axial rigidity, and kinesiophobia from those without TMD.

  Recruiting Mustafa Kemal University · Hatay · NCT07850674

• A 12-Week Trial of Flexilev with the OraFID Device and App for Parkinson's

  This study tests whether taking small, precise doses of Flexilev with the OraFID dosing device and Levilog app is acceptable and helps people with Parkinson's manage their medicine.

  Recruiting at 2 sites Phase 4 Navamedic AB · Stockholm, Stockholm County and 4 other locations · NCT07839793

• Integrated Motor-Cognitive Training in Parkinson's Disease

  This study tests a combined motor and cognitive rehabilitation program to see if people with Parkinson’s disease can stick with it and show early signs of benefit.

  Recruiting University Hospital of Ferrara · Ferrara, FE · NCT07833748

• VIM0423 for Parkinson's Tremor in Adults Not Fully Controlled by Dopaminergic Therapy

  A Vima Therapeutics study tests whether the oral drug VIM0423 can reduce tremor in adults with Parkinson’s disease who still have tremor despite dopaminergic treatment.

  Recruiting at 4 sites Phase 2 Vima Therapeutics · Scottsdale, Arizona and 29 other locations · NCT07804615

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.